tiprankstipranks
Trending News
More News >
Gilead Sciences (GILD)
NASDAQ:GILD
Advertisement

Gilead Sciences (GILD) AI Stock Analysis

Compare
13,504 Followers

Top Page

GILD

Gilead Sciences

(NASDAQ:GILD)

Rating:68Neutral
Price Target:
$131.00
▲(14.16% Upside)
Gilead Sciences' overall stock score reflects strong financial performance and positive earnings call highlights, particularly in HIV and oncology segments. However, the lack of technical analysis data and moderate valuation metrics slightly temper the score.
Positive Factors
Brand Awareness
Physician unaided brand awareness for Yeztugo is significantly higher than typical launches, at 72%.
Financial Performance
The company raised their full year revenue and EPS guides due to better than expected HIV performance.
Product Launch
Yeztugo is off to a great start with the first prescription within hours of approval and product shipped within 24 hours.
Negative Factors
Growth Challenges
The oncology and liver programs, while contributing to growth, are overshadowed by the dominant HIV portfolio, making diversification challenging.
Market Concentration Risk
There is a concentration risk in HIV and US exposure.
Market Valuation
The growth outlook for Gilead is largely priced in, with limited room for rapid growth needed to support expansion from its $150B market cap.

Gilead Sciences (GILD) vs. SPDR S&P 500 ETF (SPY)

Gilead Sciences Business Overview & Revenue Model

Company DescriptionGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
How the Company Makes MoneyGilead Sciences generates revenue primarily through the sales of its pharmaceutical products, particularly in the antiviral segment. The company’s key revenue streams include its well-established HIV and hepatitis C drug portfolios, which have historically provided significant income. Gilead also earns revenue through partnerships and collaborations with other pharmaceutical companies, research institutions, and healthcare providers, which can include licensing agreements and joint ventures. Additionally, Gilead's investments in research and development lead to new product launches that can further enhance its revenue base. The company's ability to maintain a strong market presence and adapt to changing healthcare environments, including the introduction of generics and competition, significantly impacts its earnings.

Gilead Sciences Key Performance Indicators (KPIs)

Any
Any
Product Revenue by Segment
Product Revenue by Segment
Breaks down sales figures by product lines, offering insights into which segments are most profitable and where the company might be expanding or contracting its market presence.
Chart InsightsGilead's HIV segment shows robust growth, driven by strong market leadership in products like Biktarvy, despite anticipated flat revenue in 2025 due to Medicare Part D reform. Oncology and liver disease segments are gaining momentum, supported by successful launches like Trodelvy and Livdelzi. However, Veklury sales are declining sharply as COVID-19 hospitalizations decrease. Gilead's strategic focus on pipeline advancements and cost management, including steady R&D and reduced SG&A expenses, aims to sustain growth amid these challenges and competitive pressures in cell therapies.
Data provided by:Main Street Data

Gilead Sciences Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 23, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive outlook for Gilead with significant achievements, including the FDA approval of Yeztugo and strong sales growth in the HIV segment. However, there are challenges with declining Veklury sales and competition in cell therapy, along with potential policy impacts. Overall, the highlights significantly outweigh the lowlights, indicating a strong position for Gilead moving forward.
Q2-2025 Updates
Positive Updates
FDA Approval of Yeztugo
Yeztugo, a twice-yearly injectable for HIV prevention, received FDA approval, marking a milestone in HIV treatment and prevention. The launch has seen high early uptake and awareness among healthcare providers.
Strong HIV Sales Growth
HIV product sales grew 7% year-over-year, driven by demand for Biktarvy and Descovy, which saw 9% and 35% growth respectively.
Positive Clinical Developments
Back-to-back positive Phase III results for Trodelvy in metastatic triple-negative breast cancer were announced, emphasizing its potential in first-line treatment settings.
Increased Revenue and EPS Guidance
Due to strong performance, Gilead has increased its revenue and EPS guidance for the full year.
Negative Updates
Decline in Veklury Sales
Veklury sales decreased by 44% year-over-year due to fewer COVID-19-related hospitalizations.
Challenges in Cell Therapy Sales
Cell therapy sales were down 7% year-over-year, facing competitive headwinds and lower demand.
Potential Impact of Policy Changes
Concerns were raised regarding potential impacts from policy changes such as MFN proposals and Medicaid reimbursement adjustments.
Company Guidance
During Gilead's Second Quarter 2025 Earnings Conference Call, the company announced an increase in its full-year revenue and EPS guidance, driven by strong commercial execution and operating expense discipline. Excluding Veklury, base business sales were $6.9 billion, showing a 4% year-over-year growth. Product sales reached $7.1 billion, up 2% from the previous year. HIV sales were robust, with a 7% increase year-over-year, led by Biktarvy sales of $3.5 billion, up 9%, and Descovy sales of $653 million, up 35%. The company also highlighted the successful launch of Yeztugo, with promising early feedback and a goal of achieving 75% access within six months. Gilead expects total product sales, excluding Veklury, to be in the range of $27.3 billion to $27.7 billion for the year, with an EPS range of $7.95 to $8.25.

Gilead Sciences Financial Statement Overview

Summary
Gilead Sciences presents a stable financial profile with strong profitability margins and efficient cash flow management. While revenue growth remains stagnant, the company excels in maintaining profitability and operational efficiency. The balance sheet is well-structured but carries a notable level of debt, which could be a risk factor. Despite these challenges, the company's robust cash flow generation and effective capital management provide a solid foundation for sustained financial health.
Income Statement
70
Positive
Gilead Sciences shows a steady performance with a gross profit margin of around 78.3% for TTM, indicating strong profitability. Net profit margin improved to 20.8% TTM, reflecting enhanced cost management compared to previous periods. Revenue growth is relatively flat, presenting a slight decline of 0.1% from the previous year, signaling stability in sales. EBIT margin is robust at 28.6% TTM, while EBITDA margin is healthy at 36.8% TTM, showcasing efficient operations. However, the lack of significant revenue growth could be a concern for future expansion.
Balance Sheet
65
Positive
The balance sheet exhibits solid equity with a debt-to-equity ratio of 1.3 TTM, suggesting moderate leverage. Return on equity stands at 31.1% TTM, highlighting effective use of equity to generate profits. The equity ratio is 34.0% TTM, indicating a balanced capital structure. However, the level of total debt remains substantial, which may pose risks during economic downturns. Overall, the company maintains a stable financial position with some leverage-related concerns.
Cash Flow
75
Positive
Gilead Sciences demonstrates strong cash flow generation with a free cash flow to net income ratio of 1.65 TTM, indicating efficient conversion of profits into cash. The operating cash flow to net income ratio is 1.74 TTM, reflecting strong cash earnings. Free cash flow growth has been steady, albeit with a slight decline year-over-year. Nonetheless, the company effectively manages its capital expenditures and sustains healthy cash reserves, contributing to a positive cash flow outlook.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue28.86B28.75B27.12B27.28B27.30B24.69B
Gross Profit22.67B22.50B20.62B21.62B20.70B20.12B
EBITDA10.97B4.43B10.50B8.85B11.33B4.13B
Net Income6.31B480.00M5.67B4.59B6.22B123.00M
Balance Sheet
Total Assets55.72B58.99B62.13B63.17B67.95B68.41B
Cash, Cash Equivalents and Short-Term Investments5.21B11.57B7.26B6.38B6.52B7.41B
Total Debt24.95B26.71B24.99B25.23B26.70B31.40B
Total Liabilities36.13B39.75B39.38B41.96B46.89B50.19B
Stockholders Equity19.68B19.33B22.83B21.24B21.07B18.20B
Cash Flow
Free Cash Flow9.37B10.30B7.42B8.34B10.80B7.52B
Operating Cash Flow9.87B10.83B8.01B9.07B11.38B8.17B
Investing Cash Flow-3.47B-3.45B-2.27B-2.47B-3.13B-14.62B
Financing Cash Flow-4.11B-3.43B-5.13B-6.47B-8.88B770.00M

Gilead Sciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price114.75
Price Trends
50DMA
112.71
Positive
100DMA
108.90
Positive
200DMA
103.31
Positive
Market Momentum
MACD
0.95
Positive
RSI
49.00
Neutral
STOCH
7.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GILD, the sentiment is Positive. The current price of 114.75 is below the 20-day moving average (MA) of 115.98, above the 50-day MA of 112.71, and above the 200-day MA of 103.31, indicating a neutral trend. The MACD of 0.95 indicates Positive momentum. The RSI at 49.00 is Neutral, neither overbought nor oversold. The STOCH value of 7.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GILD.

Gilead Sciences Risk Analysis

Gilead Sciences disclosed 22 risk factors in its most recent earnings report. Gilead Sciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Gilead Sciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
$142.93B13.7612.16%6.86%14.72%
81
Outperform
$212.29B13.1535.44%3.77%2.00%20.01%
76
Outperform
$122.44B12.778.39%4.40%-9.32%120.62%
68
Neutral
$141.64B22.8333.26%2.72%3.69%501.26%
68
Neutral
$95.95B19.3429.31%5.21%2.57%
67
Neutral
$155.30B24.0399.14%3.24%13.10%110.67%
51
Neutral
$7.83B-0.15-40.10%2.29%21.46%-2.01%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GILD
Gilead Sciences
114.75
38.65
50.79%
AMGN
Amgen
289.58
-29.25
-9.17%
BMY
Bristol-Myers Squibb
47.21
0.36
0.77%
MRK
Merck & Company
84.99
-28.57
-25.16%
PFE
Pfizer
24.92
-1.94
-7.22%
SNY
Sanofi
50.30
-4.08
-7.50%

Gilead Sciences Corporate Events

Executive/Board ChangesShareholder Meetings
Gilead Sciences Holds Annual Stockholders Meeting
Neutral
May 8, 2025

On May 7, 2025, Gilead Sciences held its annual meeting of stockholders, where nine directors were elected to serve for the next year. The stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the compensation of the company’s Named Executive Officers. However, several stockholder proposals, including those requesting a CEO pay ratio factor, an independent Board Chair policy, a comprehensive human rights policy, and a report on DEI practices, were not approved.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 14, 2025